DB15054

GPTKB entity

Statements (53)
Predicate Object
gptkbp:instanceOf gptkb:drug
gptkbp:approvalYear 2020
gptkbp:ATCCode J05AB16
gptkbp:bioavailability Low (prodrug, IV only)
gptkbp:brand gptkb:Veklury
gptkbp:CASNumber 1809249-37-3
gptkbp:clinicalTrialPhase Phase 3
gptkbp:contraindication hypersensitivity to remdesivir
gptkbp:developer gptkb:Gilead_Sciences
gptkbp:drugClass antiviral drug
gptkbp:eliminationHalfLife 1 hour (remdesivir), 25 hours (GS-441524)
gptkbp:hasAdministrationForm solution for infusion
gptkbp:hasApprovalCountry gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:Japan
gptkb:United_States
gptkbp:hasBoxedWarning nan
gptkbp:hasChemicalStructureType antiviral drug
gptkbp:hasDrugBankAccessionNumber gptkb:DB15054
gptkbp:hasInChIKey RWWYLEGWBNMMLJ-YSOARWBDSA-N
gptkbp:hasMolecularFormula C27H35N6O8P
gptkbp:hasPatentExpiry 2035
gptkbp:hasPatentHolder gptkb:Gilead_Sciences
gptkbp:hasPharmacokinetics Extensively metabolized to active nucleoside analog triphosphate
gptkbp:hasPregnancyWarning Use only if potential benefit justifies risk
gptkbp:hasSMILES CC(C)[C@@H](NC(=O)[C@@H](COP(=O)(OCC1=CN(C2=CC=CC=C21)C3=NC=NC=N3)O)N)C(=O)N[C@@H](C)C(=O)O
gptkbp:hasStorageCondition Store below 30°C
gptkbp:hasUNII 53V6IL329L
https://www.w3.org/2000/01/rdf-schema#label DB15054
gptkbp:indication gptkb:COVID-19
gptkb:Ebola_virus_disease_(investigational)
gptkbp:legalStatus Prescription only
gptkbp:mechanismOfAction RNA-dependent RNA polymerase inhibitor
gptkbp:metabolism Hepatic
gptkbp:molecularWeight 602.6 g/mol
gptkbp:name gptkb:Remdesivir
gptkbp:pregnancyCategory Not assigned
gptkbp:PubChem_CID 121304016
CHEMBL2016761
D11472
gptkbp:routeOfAdministration intravenous
gptkbp:sideEffect nausea
elevated liver enzymes
hypersensitivity
gptkbp:status FDA approved
EMA approved
gptkbp:synonym gptkb:GS-5734
gptkbp:target Ebola virus RNA polymerase
SARS-CoV-2 RNA polymerase
gptkbp:therapeuticArea gptkb:disease
gptkbp:bfsParent gptkb:Enhertu
gptkbp:bfsLayer 7